PHARMACOLOGY

Per ARTURSSON

SITE    

Clin Transl Sci. 2022;15:2685-2696. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Kvitne KE, Åsberg A, Johnson LK, Wegler C, Hertel JK, Artursson P, Karlsson C, Andersson S, Sandbu R, Skovlund E, Christensen H, Jansson-Löfmark R, Hjelmesaeth J, Robertsen I. PubMed

Int J Mol Sci. 2022;23:7468. Hepatic expression of the Na+-Taurocholate Cotransporting Polypeptide is independent from genetic variation. Tremmel R, Nies AT, van Eijck BAC, Handin N, Haag M, Winter S, Büttner FA, Kölz C, Klein F, Mazzola P, Hofmann U, Klein K, Hoffmann P, Nöthen MM, Gaugaz FZ, Artursson P, Schwab M, Schaeffeler E. PubMed

Clin Pharmacol Ther. 2022;111:1142-1154. Drug disposition protein quantification in matched human jejunum and liver from donors with obesity. Wegler C, Wiśniewski JR, Robertsen I, Christensen H, Kristoffer Hertel J, Hjelmesaeth J, Jansson-Löfmark R, Åsberg A, Andersson TB, Artursson P. PubMed

Pharm Res. 2022;39:1599-1613. High throughput screening of a prescription drug library for inhibitors of Organic Cation Transporter 3, OCT3. Chen EC, Matsson P, Azimi M, Zhou X, Handin N, Yee SW, Artursson P, Giacomini KM. PubMed

iScience. 2021;24:103235. Conditions for maintenance of hepatocyte differentiation and function in 3D cultures. Handin N, Mickols E, Ölander M, Rudfeldt J, Blom K, Nyberg F, Senkowski W, Urdzik J, Maturi V, Fryknäs M, Artursson P. PubMed

J Cell Physiol. 2021;236:5885-5894. Hepatocyte size fractionation allows dissection of human liver zonation. Ölander M, Wegler C, Flörkemeier I, Treyer A, Handin N, Pedersen JM, Vildhede A, Mateus A, LeCluyse EL, Urdzik J, Artursson P. PubMed

Mol Pharm. 2021;18:1792-18051. Influence of proteome profiles and intracellular drug exposure on differences in CYP cctivity in donor-matched human liver microsomes and hepatocytes. Wegler C, Matsson P, Krogstad V, Urdzik J, Christensen H, Andersson TB, Artursson P. PubMed

J Pharm Sci. 2021;110:388-396. Expanding the efflux in vitro assay toolbox: A CRISPR-Cas9 edited MDCK cell line with human BCRP and completely lacking canine MDR1. Wegler C, Gazit M, Issa K, Subramaniam S, Artursson P, Karlgren M. PubMed

Clin Pharmacol Ther. 2021;109:762-771. Proteomics-Informed Prediction of Rosuvastatin plasma profiles in patients with a wide range of body weight. Wegler C, Prieto Garcia L, Klinting S, Robertsen I, Wiśniewski JR, Hjelmesaeth J, Åsberg A, Jansson-Löfmark R, Andersson TB, Artursson P. PubMed

Chem Med Chem. 2020;15:1862-1874. The critical role of passive permeability in designing successful drugs. Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. PubMed

Liver Int. 2020;40:1770-1780. Cell-type-resolved proteomic analysis of the human liver. Ölander M, Wiśniewski JR, Artursson P. PubMed

Pharm Res. 2019;36:178. A cell-free approach based on phospholipid characterization for determination of the cell specific unbound drug fraction (fu,cell). Treyer A, Walday S, Boriss H, Matsson P, Artursson P. PubMed

Drug Metab Dispos. 2020;48:8-17. A comparative analysis of Cytochrome P450 activities in paired liver and small intestinal samples from patients with obesity. Krogstad V, Peric A, Robertsen I, Kringen MK, Wegler C, Angeles PC, Hjelmesæth J, Karlsson C, Andersson S, Artursson P, Åsberg A, Andersson TB, Christensen H. PubMed

Pharm Res. 2019;36:178. A cell-free approach based on phospholipid characterization for determination of the cell specific unbound drug fraction (fu,cell). Treyer A, Walday S, Boriss H, Matsson P, Artursson P. PubMed

Clin Pharmacol Ther. 2019;106:525-543. Towards a consensus on applying quantitative LC-MS/MS proteomics in translational pharmacology research: A white paper. Prasad B, Achour B, Artursson P, Hop CE, Lai Y, Smith PC, Barber J, Wisniewski JR, Spellman D, Uchida Y, Zientek M, Unadkat JD, Rostami-Hodjegan A. PubMed

Sci Rep. 2019;9:5850. Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations. Filppula AM, Parvizi R, Mateus A, Baranczewski P, Artursson P. PubMed   

Arch Toxicol. 2019;93:819-829. A simple approach for restoration of differentiation and function in cryopreserved human hepatocytes. Ölander M, Wiśniewski JR, Flörkemeier I, Handin N, Urdzik J, Artursson P. PubMed

J Proteome Res. 2019;18:217-224. Multiple-enzyme-digestion strategy improves accuracy and sensitivity of label- and standard-free absolute quantification to a level that is achievable by analysis with stable isotope-labeled standard ppiking. Wiśniewski JR, Wegler C, Artursson P. PubMed

Drug Metab Dispos. 2018;46:1776-1786. CRISPR-Cas9: A new addition to the drug metabolism and disposition tool Box. Karlgren M, Simoff I, Keiser M, Oswald S, Artursson P. PubMed

Mol Pharm. 2018;15:2224-2233. Intracellular drug bioavailability: effect of neutral lipids and phospholipids. Treyer A, Mateus A, Wiśniewski JR, Boriss H, Matsson P, Artursson P. PubMed

Drug Metab Dispos. 2018;46:387-396. Direct quantification of cytochromes P450 and drug transporters. A rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates. Weiß F, Hammer HS, Klein K, Planatscher H, Zanger UM, Norén A, Wegler C, Artursson P, Joos TO, Poetz O. PubMed

Mol Pharm. 2017;14:3142-3151. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer H, Artursson P. PubMed

J Pharm Sci. 2017; in press. A CRISPR-Cas9 generated Madin-Darby Canine Kidney expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies. Karlgren M, Simoff I, Backlund M, Wegler C, Keiser M, Handin N, Müller J, Lundquist P, Jareborg AC, Oswald S, Artursson P. PubMed

Proc Natl Acad Sci U S A. 2017;114:E6231-E6239. Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. Mateus A, Gordon LJ, Wayne GJ, Almqvist H, Axelsson H, Seashore-Ludlow B, Treyer A, Matsson P, Lundbäck T, West A, Hann MM, Artursson P. PubMed

J Proteomics. 2016;136:234-47. In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. Wiśniewski JR, Vildhede A, Norén A, Artursson P. PubMed

Eur J Pharm Sci. 2017;103:70-76. Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). Pedersen JM, Khan EK, Bergström CAS, Palm J, Hoogstraate J, Artursson P. PubMed

Sci Rep. 2017;7:43047. Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Mateus A, Treyer A, Wegler C, Karlgren M, Matsson P, Artursson P. PubMed

J Biomol Screen. 2016;21(2):156-64. Direct measurement of intracellular compound concentration by RapidFire Mass Spectrometry offers insights into cell permeability. Gordon LJ, Allen M, Artursson P, Hann MM, Leavens BJ, Mateus A, Readshaw S, Valko K, Wayne GJ, West A. PubMed

Anal Biochem. 2016;509:82-88. Subcellular fractionation of human liver reveals limits in global proteomic quantification from isolated fractions. Wiśniewski JR, Wegler C, Artursson P. PubMed

Trends Pharmacol Sci. 2016;37:243-5. The need for speed-kinetic limits of drug transporters. Matsson P, Lundquist P, Artursson P. PubMed

J Pharm Sci. 2016;105:1017-21. Complete knockout of endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. Simoff I, Karlgren M, Backlund M, Lindström AC, Gaugaz FZ, Matsson P, Artursson P. PubMed

J Pharm Sci. 2016;105:817-27. The Proteome of filter-grown Caco-2 Cells with a focus on proteins involved in drug disposition. Ölander M, Wiśniewski JR, Matsson P, Lundquist P, Artursson P. PubMed

Drug Metab Dispos. 2016;44:505-16. Mechanistic modeling of Pitavastatin disposition in Sandwich-Cultured Human Hepatocytes: a proteomics-informed bottom-up approach. Vildhede A, Mateus A, Khan EK, Lai Y, Karlgren M, Artursson P, Kjellsson MC. PubMed

Adv Drug Deliv Rev. 2016;106(Pt B):256-276. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. Lundquist P, Artursson P. PubMed

Science. 2015;347:716-7. Structural biology. Breaking the intestinal barrier to deliver drugs. Artursson P, Knight SD. PubMed

J Proteome Res. 2015;14:3305-14. Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure. Vildhede A, Wiśniewski JR, Norén A, Karlgren M, Artursson P. PubMed

Trends Pharmacol Sci. 2015;36:255-62. Quantifying the impact of transporters on cellular drug permeability. Matsson P, Fenu LA, Lundquist P, Wiśniewski JR, Kansy M, Artursson P. PubMed

Drug Metab Dispos. 2014;42:1210-8. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions.Vildhede A, Karlgren M, Svedberg EK, Wisniewski JR, Lai Y, Norén A, Artursson P. PubMed

Mol Pharm. 2014;11:1727-38. Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. Smith D, Artursson P, Avdeef A, Di L, Ecker GF, Faller B, Houston JB, Kansy M, Kerns EH, Krämer SD, Lennernäs H, van de Waterbeemd H, Sugano K, Testa B. PubMed

J Med Chem. 2014;57:3005-10. A high-throughput cell-based method to predict the unbound drug fraction in the brain. Mateus A, Matsson P, Artursson P. PubMed

J Med Chem. 2014;57:2746-54. Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. Over B, McCarren P, Artursson P, Foley M, Giordanetto F, Grönberg G, Hilgendorf C, Lee MD 4th, Matsson P, Muncipinto G, Pellisson M, Perry MW, Svensson R, Duvall JR, Kihlberg J. PubMed

Eur J Pharm Sci. 2014;57:173-99. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Bergström CA, Holm R, Jørgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnes J, Taylor R, Mullertz A. PubMed

Mol Pharm. 2013;10:4252-62. Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. Matsson EM, Eriksson UG, Palm JE, Artursson P, Karlgren M, Lazorova L, Brännström M, Ekdahl A, Dunér K, Knutson L, Johansson S, Schützer KM, Lennernäs H. PubMed

Toxicol Sci. 2013;136:328-43. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Pedersen JM, Matsson P, Bergström CA, Hoogstraate J, Norén A, LeCluyse EL, Artursson P. PubMed

Mol Pharm. 2013;10:3152-63. An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. Neve EP, Artursson P, Ingelman-Sundberg M, Karlgren M. PubMed

Mol Pharm. 2013;10:2467-78. Rapid measurement of intracellular unbound drug concentrations. Mateus A, Matsson P, Artursson P. PubMed

Clin Pharmacol Ther. 2013;94:30-2. Computational prospecting for drug-transporter interactions. Matsson P, Artursson P. PubMed

J Med Chem. 2012;55:4740-63. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. PubMed

Drug Discov Today. 2012;17:905-12. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Di L, Artursson P, Avdeef A, Ecker GF, Faller B, Fischer H, Houston JB, Kansy M, Kerns EH, Krämer SD, Lennernäs H, Sugano K. PubMed

Pharm Res. 2012;29:411-26. In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Karlgren M, Ahlin G, Bergström CA, Svensson R, Palm J, Artursson P. PubMed

Nat Rev Drug Discov. 2010;9:597-614. Coexistence of passive and carrier-mediated processes in drug transport. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, Ecker GF, Faller B, Fischer H, Gerebtzoff G, Lennernaes H, Senner F. PubMed

Pharmacogenomics J. 2011;11:400-11.Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL, Giacomini KM, Artursson P. PubMed

Drug Metab Dispos. 2009;37:2275-83. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Ahlin G, Hilgendorf C, Karlsson J, Szigyarto CA, Uhlén M, Artursson P. PubMed

Pharm Res. 2009;26:1816-31. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. PubMed

J Med Chem. 2008;51:5932-42. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, Artursson P. PubMed

J Med Chem. 2008;51:3275-87. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. PubMed